Hoth Therapeutics' Novel Cancer Drug Prevented Cell Growth, Induced Cell Death Over 72 hours

Hoth Therapeutics Inc (NASDAQ:HOTH) shares are surging after announcing development updates for its novel cancer therapeutic, HT-KIT.

• Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-KIT mRNA frame-shifting approach on mast cell leukemia cells in vitro.
• The researchers found that KIT protein expression, signaling and function were reduced. 
• Treatment with HT-KIT prevented cancer cell growth and induced cell death over 72 hours. 
• In a humanized mast cell leukemia mouse model, tumor growth and infiltration of other organs were reduced, and tumor cell death increased when HT-KIT induced frameshifted c-KIT mRNA. 
• Hoth has filed several patent applications to protect this IP throughout the world.  
• "Our next round of preclinical studies are underway. We are excited to utilize the results for our planned Pre-IND meeting with the FDA later this year," stated Robb Knie, Chief Executive Officer of Hoth.
• HT-KIT, a new molecular entity, was designated as an Orphan Drug to treat mastocytosis earlier in 2022. 
• Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms to develop HT-KIT, a rare, aggressive cancer with a poor prognosis.
• Price Action: HOTH shares are up 111.1% at $1.30 during the market session on the last check Monday.